Study guide

4.3 Transplant Immunology & Immune Pharmacology

NBME Comprehensive Basic Science Examination CBSE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Navigation

1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness

2 Human Development

2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care

3 Blood & Hematologic Disease

3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms

4 Immune System

4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology

5 Nervous System Anatomy & Disease

5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms

6 Behavioral Health

6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science

7 Musculoskeletal System

7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders

8 Skin & Soft Tissue

8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection

9 Cardiovascular Pathophysiology

9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension

10 Cardiovascular Pharmacology

10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs

11 Respiratory System

11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology

12 Renal Physiology & Electrolytes

12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation

13 Renal Pathology

13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease

14 Gastrointestinal System

14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption

15 Endocrine System

15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome

16 Reproductive System

16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia

17 Multisystem Processes & Disorders

17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology

18 Biostatistics & Epidemiology

18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health

19 Social Sciences & Communication

19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning

20 Integrated Disciplines Capstone

20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution

4.3 Transplant Immunology & Immune Pharmacology

Key Takeaways Explain This Topic AI

Hyperacute rejection is preformed antibody + complement (minutes); acute is T-cell (± antibody) within days–weeks; chronic is fibrosis/vasculopathy over months–years.

GVHD occurs when donor T cells attack immunocompromised host tissues (skin, liver, gut), typically after allogeneic HSCT.

HLA matching minimizes allorecognition of foreign MHC–peptide complexes that drive T-cell rejection.

Calcineurin inhibitors block NFAT-dependent IL-2 transcription; mTOR inhibitors block IL-2–driven cell-cycle progression; antimetabolites impair lymphocyte proliferation.

Glucocorticoids broadly suppress NF-κB/cytokines; anti-TNF agents neutralize TNF-α; anti-CD20 depletes B cells—each with characteristic mechanism-linked toxicities.

Last updated: August 2026

Allorecognition: Why Foreign Grafts Are Seen

Transplanted tissues express donor MHC (HLA) molecules loaded with peptides. Recipient T cells recognize foreign MHC directly on graft APCs ( direct allorecognition ) or process donor antigens presented on recipient APCs ( indirect allorecognition ). Because TCR repertoires are selected on self-MHC, many clones cross-react strongly with allogeneic MHC—explaining vigorous rejection without prior sensitization in some settings, and even stronger responses when memory exists.

HLA matching concept

HLA genes are highly polymorphic. Closer matching at key loci (especially HLA-A, -B, and -DR in many solid-organ and HSCT contexts) reduces the density of foreign epitopes that T cells attack, lowering rejection and GVHD risk. Perfect matching is not always available; immunosuppression compensates. ABO blood-group compatibility remains critical because preformed isohemagglutinins can destroy grafts—linking transfusion rules to hyperacute risk.

  • Matching theme Why it matters
  • HLA class I (A, B) CD8 allorecognition; HSCT engraftment/GVHD balance
  • HLA class II (DR) CD4 help driving cellular and humoral rejection
  • ABO Preformed natural antibodies → hyperacute risk if incompatible
  • Crossmatch Detects preformed donor-specific antibodies before implant
  • Rejection Timing and Mechanisms

Rejection Timing Dominant mechanism Histology/clinical cues

Hyperacute Minutes to hours Preformed DSA (IgG) + complement → thrombosis, necrosis Gross cyanosis of graft; neutrophil infiltrates; fibrin thrombi; prevented by crossmatch/ABO check

Acute Days to weeks (or later if drugs tapered) T-cell cytotoxicity and inflammation; can include acute antibody-mediated rejection with C4d Lymphocytic infiltrate, endotheliitis; rising creatinine in kidney; treatable if caught

Chronic Months to years Smoldering alloimmune + nonimmune injury → fibrosis, vascular intimal thickening Graft arteriosclerosis, interstitial fibrosis; progressive dysfunction

Hyperacute is a Type II-like endothelial attack by preformed antibodies (prior transplant, pregnancy, transfusion). Acute cellular rejection is largely Type IV (CD4 help + CD8 killing of graft cells). Acute humoral rejection uses donor-specific antibodies with complement activation (C4d staining is a pathology marker of classical pathway activity on endothelium). Chronic rejection combines repeated immune injury with ischemia and drug toxicity, producing irreversible scarring.

Graft-versus-Host Disease (GVHD)

In allogeneic hematopoietic stem-cell transplantation , the graft contains mature donor T cells. If the host is immunocompromised and tissues express alloantigens the donor T cells recognize, those T cells attack host skin (rash), liver (jaundice, enzyme rise), and gut (diarrhea)—classic GVHD triad. Acute GVHD is largely alloreactive T-cell–driven; chronic GVHD has autoimmune-like fibrosis features. Host-versus-graft dominates solid-organ rejection; graft-versus-host dominates when the immune system itself is transplanted. Mild graft-versus-tumor effects can be beneficial in leukemia, illustrating the double edge of alloreactivity.

Immune Pharmacology: Mechanism First, Toxicity Linked

Immunosuppressants interrupt activation, IL-2 signaling, proliferation, or specific cytokines/cells. Learn where in the pathway each class acts, then the predictable adverse effects of that mechanism.

Calcineurin inhibitors (cyclosporine, tacrolimus)

TCR signaling raises calcium → calcineurin dephosphorylates NFAT → NFAT enters the nucleus and drives IL-2 (and other) transcription. Calcineurin inhibitors bind immunophilins (cyclosporine–cyclophilin; tacrolimus–FKBP) and block calcineurin, starving T-cell IL-2 production. Classic toxicities: nephrotoxicity, hypertension, neurotoxicity (tremor); cyclosporine is associated with gingival hyperplasia and hirsutism; tacrolimus with more glucose intolerance—details vary by source but nephrotoxicity is shared and high-yield.

mTOR inhibitors (sirolimus/rapamycin, everolimus)

IL-2 receptor signaling activates PI3K–Akt– mTOR , promoting cell-cycle progression and proliferation. mTOR inhibitors complex with FKBP and block mTOR, arresting lymphocytes in G1 even if IL-2 is present. They are often synergistic with calcineurin inhibitors but used carefully because of impaired wound healing , hyperlipidemia, and cytopenias/mouth ulcers—consistent with antiproliferative effects on nonimmune tissues.

Antimetabolites (azathioprine, mycophenolate mofetil)

Azathioprine is converted to 6-mercaptopurine metabolites that inhibit purine synthesis, impairing lymphocyte proliferation (lymphocytes depend on de novo purine pathways). TPMT deficiency increases myelotoxicity risk—classic pharmacogenetic pearl. Mycophenolate inhibits inosine monophosphate dehydrogenase (IMPDH) , preferentially blocking guanosine synthesis in lymphocytes. Toxicities: myelosuppression, GI upset; infection risk from global lymphocyte impairment.

Glucocorticoids (prednisone and congeners)

Genomic effects: glucocorticoid receptor modulates transcription, broadly suppressing NF-κB –driven cytokines (IL-1, IL-6, TNF, etc.), reducing leukocyte trafficking, and inducing apoptosis of some lymphoid cells. Used for induction, rejection pulses, and autoimmunity. Toxicities reflect physiology of excess cortisol: hyperglycemia, osteoporosis, Cushingoid habitus, HPA suppression, infection risk, impaired wound healing, mood changes—not single-pathway specific but highly testable as class effects.

Biologics: anti-TNF and anti-CD20

Agent class Target Mechanism High-yield risks/associations

Anti-TNF (infliximab, adalimumab, etanercept) TNF-α Neutralize soluble (and some membrane) TNF → less endothelial activation, leukocyte recruitment, synovial inflammation Reactivation of latent TB and other granulomatous infections; demyelination/heart-failure cautions in practice

Anti-CD20 (rituximab) CD20 on B cells Depletes B cells (ADCC/complement/apoptosis) → reduces autoantibody production and B-cell APC function Infusion reactions; hepatitis B reactivation; hypogammaglobulinemia with repeated use; progressive multifocal leukoencephalopathy rare but serious

Anti-TNF agents illustrate that TNF is essential for macrophage containment of mycobacteria—blocking it removes a checkpoint that keeps latent TB sequestered. Anti-CD20 shows that B cells contribute both antibody and antigen presentation; depletion helps antibody-mediated autoimmunity (e.g., some RA, vasculitis, pemphigus contexts) and certain lymphomas.

Other pathway notes (high-yield adjacency)

Basiliximab/daclizumab -type IL-2 receptor (CD25) antibodies block IL-2 growth signals on activated T cells (induction). Belatacept (CTLA-4–Ig family) blocks B7–CD28 costimulation, promoting anergy. ATG depletes T cells. These reinforce the same activation cascade: signal 1 (TCR–MHC), signal 2 (costimulation), signal 3 (cytokines/IL-2).

Integrated Clinical–Mechanism Cases

Immediate graft thrombosis with positive crossmatch → hyperacute , preformed antibody/complement; no drug on earth reverses minutes-scale MAC/thrombosis—prevention is the lesson.

Week-2 rising creatinine, lymphocytic tubulitis after living-donor kidney → acute T-cell rejection ; escalate steroids/optimize calcineurin inhibitor.

Years later, progressive fibrosis and concentric vascular thickening → chronic rejection .

Post-HSCT rash + diarrhea + bilirubin rise → GVHD from donor T cells.

RA patient on infliximab develops reactivation TB → anti-TNF removed granuloma integrity.

Transplant patient on tacrolimus with rising creatinine → calcineurin-inhibitor nephrotoxicity versus rejection must be distinguished clinically, but mechanism of drug injury is afferent arteriolar vasoconstriction/toxicity from calcineurin blockade in the kidney.

Summary Table: Drug Class → Pathway Node

  • Class Pathway node blocked
  • Calcineurin inhibitors Ca2+–calcineurin–NFAT → IL-2 transcription
  • mTOR inhibitors IL-2R → mTOR proliferation signaling
  • Antimetabolites Nucleotide synthesis → clonal expansion
  • Glucocorticoids Broad cytokine gene programs / trafficking
  • Anti-TNF Effector cytokine TNF-α
  • Anti-CD20 B-cell lineage survival/effector pool

Master these nodes and the rejection timing table; most CBSE transplant/immunopharmacology items are recombinations of the same mechanism map rather than obscure drug trivia.